Quick Dispatch:
Your foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis ships.
Need Help?
Questions about foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis in your area.
TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER'S DISEASE: SENOLYTICS • The Journal of Prevention of Alzheimer's Disease
25.01
Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis
28.88
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
27.67
Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment
20.89
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
23.25
Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
24.25
Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases
23.20
